Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Carlos Alberto Gomez-Roca"'
Autor:
Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we
Externí odkaz:
https://doaj.org/article/189773f2417346dcbdf8b6281d57effa
Autor:
Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dréno, Stéphane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2023, Online ahead of print. ⟨10.1200/JCO.22.02072⟩
Journal of Clinical Oncology, 2023, Online ahead of print. ⟨10.1200/JCO.22.02072⟩
PURPOSE Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti–programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4b28765b673f8d282e8b6a6a86470d
https://www.zora.uzh.ch/id/eprint/234148/
https://www.zora.uzh.ch/id/eprint/234148/
Autor:
Emiliano Calvo Aller, Glenn Hanna, Maria Vieito Villar, Caroline Even, Victor Moreno, Chul Kim, Shuchi Gulati, Daniel Morgensztern, Ana Acuna-Villaorduna, Philippe Cassier, Dennie Jones, Florilene Bouisset, Daniela Sahlender, Elisabeth Rouits, Dany Spaggiari, Lars Damstrup, Carlos-Alberto Gomez-Roca
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Hardaker, Elizabeth L., Sanseviero, Emilio, Karmokar, Ankur, Taylor, Devon, Milo, Marta, Michaloglou, Chrysis, Hughes, Adina, Mai, Mimi, King, Matthew, Solanki, Anisha, Magiera, Lukasz, Miragaia, Ricardo, Kar, Gozde, Standifer, Nathan, Surace, Michael, Gill, Shaan, Peter, Alison, Talbot, Sara, Tohumeken, Sehmus, Fryer, Henderson
Publikováno v:
Nature Communications; 2/24/2024, Vol. 15 Issue 1, p1-20, 20p
Publikováno v:
Immunotherapy Weekly; 3/19/2024, p578-578, 1p